1.    United Nations. (http://social.un.org/index/Youth/FAQs.aspx) Definition: Youth-15~24yrs.Teenagers-13~19yrs. Young adult-20~24yrs.

2.    WCD survey 2011; Clueless or Clued up: Your Right to be informed about contraception survey.Fieldwork carried out by GFK Healthcare. April-May 2011.

3.    TNS survey 2011.

4.    Wiegratz I, Thaler CJ. (2011), Hormonal contraception--what kind, when, and for whom? Dtsch Arztebl Int. 108(28-29): 495–506.

5.    Medical eligibility criteria for contraceptive use, Fourth edition,2009

6.    Bitzer J. (2009), The added benefits of contracetion. Gynaecology Forum,14(1)3.

7.    Howard Ory et al.(1976) Oral Contraceptives and Reduced Risk of Benign Breast Diseases,N Engl J Med. 294:419-422.

8.    Bachmann G. et al.,(2004) Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 70(3):191-8.

9.    Collaborative Group on Epidemiological Studies of Ovarian Cancer Lancet. et al.,(2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 371(9609):303-14.

10.  Maguire K, Westhoff C., (2011) The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol. 205(4 Suppl):S4-8.

11.  Oner G, Muderris II.,(2011) A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone   24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception. 84(5):508-11. Epub 2011 Apr 15.

12.  Vessey MP, Metcalfe A, Wells C, et al.( 1987) Ovarian neoplasm, functional ovarian cysts and oral contraceptives. Br Med J.; 294: 1518 -1520.

13.  Marchbanks PA. et al.( 2002) Oral contraceptives and the risk of breast cancer. N Engl J Med. ;346(26):2025-32.

14.  Vessey M, Painter R., (2006) Oral contraceptive use and cancer. Finding in a large cohort study, 1968-2004. Br J Cancer. 95(3):385-9. Epub 2006 Jul 4.

15.  Toivonen J, Luukkainen T, Allonen H,(1991) Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol;77:261-264.

16.  Spencer AL, Bonnema R, McNamara MC.(2009) Helping women choose appropriate hormonal contraception: on risks, benefits, and indications. Am J Med.122(6):497-506.

17.  Klaas Heinemann , Lothar A J Heinemann,( 2011) Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel. J Fam Plann Reprod Health Care .37:132-135;                 doi:10.1136/jfprhc-2011-14524

18.  Hannaford PC.et al., (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study.;Br Med J 335(7621):651.

19.  Hernádi, L. et al. (2009)Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception 80 18–24

20.  Amy JJ, Tripathi V (2009) Contraception for women: an evidence based overview Br Med J ; 339:563-568.

21.  Rohan TE, Miller AB.(1999)A cohort study of oral contraceptive use and risk of benign breast disease.Int J Cancer 82:191-6.

22.  Pitashny M. et al.(2005) Oral contraceptives: their mode of action and dermatologic applications. Skinmed. Mar-Apr;4(2):101-6.

23.  J.Vrb1´kova´1 and D.Cibula (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update, Vol.11, No.3 pp. 277–291

24.  Arowojolu AO.et al.,(2012) Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev.7:CD004425.

25.  Yonkers KA.et al.(2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 106(3):492-501

26.  Pearlstein TB.et al.(2005), Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception.;72(6):414-21. Epub 2005 Nov 2.

27.  Functional Ovarian Cysts and Oral Contraceptives: Negative Association Confirmed Surgically. JAMA. 1974;228(1):68-69.

28.  Ness RB. et al.,(2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol. 152(3):233-41.

29.  Iodice S, Barile M, Rotmensz N, et al.(2010) Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46: 2275-84.

30.  Roberta B. Ness,et al.(2011) Contraception Methods, beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer.Ann Epidemiol. 21(3): 188–196.

31.  Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987;257(6):796-800.

32.  Kaufman DW.et al., (1980) Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med.; 303(18):1045-7.

33.  Hulka BS. et al. (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA. 22-29;247(4):475-7.

34.  Jick SS, Walker AM, Jick H.(1993) Oral contraceptives and endometrial cancer. Obstet Gynecol. 82(6):931-5.

35.  Cibula D. et al., (2010) Hormonal contraception and risk of cancer. Hum Reprod Update.;16(6):631-50. Epub 2010 Jun 12.

36.  Bosetti C. et al., (2009) Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update.15(5):489-98.

37.  Fernandez E. et al., (2001) Oral contraceptives and colorectal cancer risk: a meta-analysis.Br J Cancer.; 84(5):722-7.

38.  Wølner-Hanssen P. et al.,(1990) Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA. 263(1):54-9.

39.  Burkman R, Schlesselman JJ, Zieman M. (2004) Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 190(4 Suppl):S5-22.

40.  Shelley S. Tworoger et al.,(2007) Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk Am J Epidemiol 166(8):894–901.

41.  Dinger J, et al. (2011) Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. Obstet Gynecol;117:33-40

42.  US Prescribing Information for Combination Oral Contraceptives (YAZ) (2012) Fig 2.

43.  Heit JA et al., (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 143(10): 697-706

44.  Dinger JC et al., (2007) The safety of a drospirenone-containing oral contraceptive final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 75(5): 344-54

45.  Heinemann LA & Dinger JC. (2007) Range of published estimates of venous thromboembolism incidence in young women. Contraception. 75(5): 328-36

46.  James A. (2011) Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol. 118(3): 718-29

47.  Guillebaud J.,(2012) Contraception Today, seventh edition.page15.

48.  Collaborative Group on Hormonal Factors in Breast Cancer. (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet;347(9017):1713-27.

49.  Kahlenborn C, et al. Oral contraceptive use as a risk factor for premenopausal breast cancer: a metaanalysis. Mayo Clin Proc 2006;81(10):1290-302.